Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBITDA Margin (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EBITDA Margin data on record, last reported at 373232.42% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 37267462.0% year-over-year to 373232.42%; the TTM value through Sep 2025 reached 7248.99%, up 736956.0%, while the annual FY2024 figure was 396.76%, 30876.0% down from the prior year.
  • EBITDA Margin reached 373232.42% in Q3 2025 per CAPR's latest filing, down from 189026.83% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 542.64% in Q4 2024 and bottomed at 373232.42% in Q3 2025.
  • Average EBITDA Margin over 5 years is 38871.4%, with a median of 392.26% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: skyrocketed 469245bps in 2021, then crashed -37267462bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 2326.65% in 2021, then surged by 65bps to 804.65% in 2022, then soared by 99bps to 5.43% in 2023, then soared by 10084bps to 542.64% in 2024, then plummeted by -68881bps to 373232.42% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 373232.42% in Q3 2025, 189026.83% in Q1 2025, and 542.64% in Q4 2024.